Cellectis: the award of Nobel Prize in Medicine to Professor Yamanaka confirms the relevance of the Group’s stem cell strategy

Published on October 08, 2012

Back to all press releases

Paris, France, October 8th, 2012 - Cellectis (Alternext: ALCLS), the French genome engineering specialist, considers the award of the Nobel Prize fin Medicine to Professor Shinya Yamanaka as the validation of its stem cell strategy and is a major growth driver for this activity. Since 2010 Cellectis started collaborating with Professor Shinya Yamanaka at the Center for iPS Cell Research and Application (CiRA) at Kyoto, Japan, working together on genome engineering of induced pluripotent stem (iPS) cells.

Cellectis holds license agreements for Professor Yamanaka’s induced pluripotent stem cell (iPS) patents since 2010 and already markets products using this technology.


Since then, Cellectis has successively:

  • taken licenses on founding patents from Shinya Yamanaka’s works;
  • developed an on-going scientific collaboration with Prof. Yamanaka's team at CiRA with an exchange of technologies for genome engineering developed by Cellectis and iPS technologies of CiRA), and with other centers of excellence, including I-Stem;
  • structured the Business Unit Cellectis stem cells with the creation of a subsidiary located in Evry’s Genopole with the Caisse des Dépôts et Consignations, and the acquisition of stem cell historical leader in Europe.

Cellectis already sells cellular models for research and drug development within pharmaceutical industry, implementing technologies developed by CiRA. In addition, Cellectis is currently working on a number of develops large-scale projects based on iPS cell technology with two aims:

  • personalized medicine (or "custom medicine") to orient new drugs to patients who can benefit from them
  • regenerative medicine, making an iPS bank for clinic research, strategic resource for the entire industry of cell therapy.

André Choulika, CEO of Cellectis, declares: "the quality of relations between the teams of CiRA and Cellectis Group - based on mutual respect of their scientific expertise on the one hand, the recognition of the strong complementarity of their knowledge on the other - involved the establishment of a real alliance able to compete with the American presence in the area." Cellectis plans to expand and deepen this collaboration with Prof. Yamanaka in order to strengthen its position as an industry leader, increase its activity remaining at the forefront of iPS cell technology, and develop industry standards in regenerative medicine.

Download the PDF file